FDA In Brief: FDA issues draft guidance to foster oncology product development for pediatric populations | FDA

FDA In Brief: FDA issues draft guidance to foster oncology product development for pediatric populations | FDA

FDA issues draft guidance to foster oncology product development for pediatric populations

Today, the U.S. Food and Drug Administration issued a draft guidance document, “FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act.” The draft guidance addresses early planning for pediatric evaluation of certain molecularly targeted oncology drugs for which original new drug applications (NDAs) and biologics license applications (BLAs) are expected to be submitted to the FDA on or after August 18, 2020, in accordance with section 505B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which was amended by the FDA Reauthorization Act of 2017 (FDARA).

Learn More